排序方式: 共有14条查询结果,搜索用时 0 毫秒
1.
Huber Timo Steininger Philipp Irrgang Pascal Korn Klaus Tenbusch Matthias Diesch Katharina Achenbach Susanne Kremer Andreas E. Werblow Marissa Vetter Marcel Bogdan Christian Held Jürgen 《European journal of clinical microbiology & infectious diseases》2021,40(9):1999-2004
European Journal of Clinical Microbiology & Infectious Diseases - 相似文献
2.
Huber Timo Steininger Philipp Irrgang Pascal Korn Klaus Tenbusch Matthias Diesch Katharina Achenbach Susanne Kremer Andreas E. Werblow Marissa Vetter Marcel Bogdan Christian Held Jürgen 《European journal of clinical microbiology & infectious diseases》2021,40(9):1983-1997
European Journal of Clinical Microbiology & Infectious Diseases - SARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly... 相似文献
3.
Andreas E. Kremer Anita N. Kremer Carsten Willam Simon Völkl Johan Verhagen Susanne Achenbach Edith D. van der Meijden Vanessa Lang Michael Aigner Clara Maier Matthias Tenbusch Klaus Korn Gloria Lutzny-Geier Silvia Spoerl Richard Strauß Marcel Vetter Klaus Überla Markus F. Neurath Andreas Mackensen Mario Schiffer Holger Hackstein 《European journal of immunology》2021,51(10):2478-2484
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key requisite in the fight against viral infections. Patients depleted of antibody-producing B cells, such as those treated with rituximab (anti-CD20) for hematological malignancies, lack a fundamental part of their adaptive immunity. Treatment with convalescent plasma appears to be of general benefit in this particularly vulnerable cohort. We analyzed clinical course and inflammation markers of three B-cell-depleted patients suffering from COVID-19 who were treated with convalescent plasma. In addition, we measured serum antibody levels as well as peripheral blood CD38/HLA-DR-positive T-cells ex vivo and CD137-positive T-cells after in vitro stimulation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides in these patients. We observed that therapy with convalescent plasma was effective in all three patients and analysis of CD137-positive T-cells after stimulation with SARS-CoV-2 peptides showed an increase in peptide-specific T-cells after application of convalescent plasma. In conclusion, we here demonstrate efficacy of convalescent plasma therapy in three B-cell-depleted patients and present data that suggest that while application of convalescent plasma elevates systemic antibody levels only transiently, it may also boost specific T-cell responses. 相似文献
4.
5.
6.
7.
Tenbusch FJ 《Journal of the American Dental Association (1939)》2000,131(7):858, 860
8.
A. Potthoff S. Schwannecke G. Nabi D. Hoffmann T. Grunwald O. Wildner N.H. Brockmeyer K. Überla M. Tenbusch 《Vaccine》2009
Since intradermal delivery of DNA vaccines via tattoo device is an efficient strategy to induce antigen-specific immune responses, we evaluated this route of application for adenoviral vector vaccines in mice. Although expression levels were comparable after i.d. injection and i.d. tattoo immunization of adenoviral vectors, the tattoo application confined antigen expression to the upper layers of the dermis. Both delivery approaches resulted in strong CD8+ T-cell and humoral immune responses to three different antigens and conferred protection against mucosal challenge with respiratory syncytial virus. However, in contrast to results obtained with DNA vaccines, intradermal tattoo immunization did not provide any obvious advantage in comparison to simple intradermal injection of the adenoviral vector vaccines. 相似文献
9.
Ralf Wagner David Peterhoff Stephanie Beileke Felix Günther Melanie Berr Sebastian Einhauser Anja Schütz Hans Helmut Niller Philipp Steininger Antje Knll Matthias Tenbusch Clara Maier Klaus Korn Klaus J. Stark Andr Gessner Ralph Burkhardt Michael Kabesch Holger Schedl Helmut Küchenhoff Annette B. Pfahlberg Iris M. Heid Olaf Gefeller Klaus Überla 《Viruses》2021,13(6)
SARS-CoV-2 infection fatality ratios (IFR) remain controversially discussed with implications for political measures. The German county of Tirschenreuth suffered a severe SARS-CoV-2 outbreak in spring 2020, with particularly high case fatality ratio (CFR). To estimate seroprevalence, underreported infections, and IFR for the Tirschenreuth population aged ≥14 years in June/July 2020, we conducted a population-based study including home visits for the elderly, and analyzed 4203 participants for SARS-CoV-2 antibodies via three antibody tests. Latent class analysis yielded 8.6% standardized county-wide seroprevalence, a factor of underreported infections of 5.0, and 2.5% overall IFR. Seroprevalence was two-fold higher among medical workers and one third among current smokers with similar proportions of registered infections. While seroprevalence did not show an age-trend, the factor of underreported infections was 12.2 in the young versus 1.7 for ≥85-year-old. Age-specific IFRs were <0.5% below 60 years of age, 1.0% for age 60–69, and 13.2% for age 70+. Senior care homes accounted for 45% of COVID-19-related deaths, reflected by an IFR of 7.5% among individuals aged 70+ and an overall IFR of 1.4% when excluding senior care home residents from our computation. Our data underscore senior care home infections as key determinant of IFR additionally to age, insufficient targeted testing in the young, and the need for further investigations on behavioral or molecular causes of the fewer infections among current smokers. 相似文献
10.
Silvia Spoerl Anita N. Kremer Michael Aigner Nina Eisenhauer Pauline Koch Lina Meretuk Patrick Löffler Matthias Tenbusch Clara Maier Klaus Überla Lucie Heinzerling Benjamin Frey Gloria Lutzny-Geier Thomas H. Winkler Gerhard Krönke Marcel Vetter Heiko Bruns Markus F. Neurath Andreas Mackensen Andreas E. Kremer Simon Völkl 《European journal of immunology》2021,51(6):1436-1448
COVID-19 is a life-threatening disease leading to bilateral pneumonia and respiratory failure. The underlying reasons why a smaller percentage of patients present with severe pulmonary symptoms whereas the majority is only mildly affected are to date not well understood. Comparing the immunological phenotype in healthy donors and patients with mild versus severe COVID-19 shows that in COVID-19 patients, NK-/B-cell activation and proliferation are enhanced independent of severity. As an important precondition for effective antibody responses, T-follicular helper cells and antibody secreting cells are increased both in patients with mild and severe SARS-CoV-2 infection. Beyond this, T cells in COVID-19 patients exhibit a stronger activation profile with differentiation toward effector cell phenotypes. Importantly, when looking at the rates of pulmonary complications in COVID-19 patients, the chemokine receptor CCR4 is higher expressed by both CD4 and CD8 T cells of patients with severe COVID-19. This raises the hypothesis that CCR4 upregulation on T cells in the pathogenesis of COVID-19 promotes stronger T-cell attraction to the lungs leading to increased immune activation with presumably higher pulmonary toxicity. Our study contributes significantly to the understanding of the immunological changes during COVID-19, as new therapeutic agents, preferentially targeting the immune system, are highly warranted. 相似文献